Coppola Angelo, Flores Krisstopher Richard, De Filippis Francesca
UOC Malattie dell'Apparato Respiratorio, Ospedale "Regina Apostolorum", Albano Laziale, RM, Italy.
Respir Med Case Rep. 2020 Apr 4;30:101050. doi: 10.1016/j.rmcr.2020.101050. eCollection 2020.
A 63 years - old woman affected by severe eosinophilic asthma associated with EGPA presented refractory respiratory symptoms, resistant to high dose oral corticosteroid treatment. A significant hyper-eosinophilia was present at the blood test, and the ACT score was steadily low, despite the maximal dose of inhalation therapy. The CT chest scan showed a persistent diffuse bronchial wall thickening, pulmonary infiltration and paranasal sinusitis. We report here the rapid onset of effect of benralizumab 30 mg in a monthly subcutaneous injection in reducing patient's symptom, inducing regression of CT scan abnormalities, determining a steroid sparing effect and improving lung function tests after 3 months of therapy. A fast and stable reduction of peripheral eosinophilia associated with an increase in ACT score were also documented after the first dose of benralizumab.
一名63岁患有与嗜酸性肉芽肿性多血管炎（EGPA）相关的严重嗜酸性粒细胞性哮喘的女性出现难治性呼吸道症状，对高剂量口服糖皮质激素治疗耐药。血液检查显示明显的嗜酸性粒细胞增多，尽管进行了最大剂量的吸入治疗，但哮喘控制测试（ACT）评分持续较低。胸部CT扫描显示持续的弥漫性支气管壁增厚、肺部浸润和鼻窦炎。我们在此报告，每月皮下注射30mg贝那利珠单抗后效果迅速显现，可减轻患者症状，使CT扫描异常消退，产生激素节省效应，并在治疗3个月后改善肺功能测试结果。首次注射贝那利珠单抗后还记录到外周嗜酸性粒细胞快速且稳定地减少，同时ACT评分增加。
